The Contributions of Scott Rocklage to the Success of 5AM Ventures

Scott Rocklage is a managing partner at 5AM Ventures. He assumed this role in 2004. Scott had initially joined 5AM Ventures as a Venture Partner in 2003. Scott Rocklage has been in healthcare management for over 30 years. He also has a strong scientific background that has greatly helped with his career.

His great leadership skills helped him obtain approval from the Federal Drug Administration for three drug applications. The drugs included Teslascan, Omniscan, and Cubicin. 5AM Ventures has offices in Waltham, California, and San Francisco. Read more: Scott Racklage | Bloomberg

Before 5AM, Scott Rocklage was the Chief Operating Officer and Chairman of Cubist Pharmaceuticals. He also worked at Nycomed Salutar as CEO and President. While at Salutar, Scott held several Design and Research positions. He has also held President and CEO position at Amersham Health and Co-President and Executive Chairman of Ilypsa, Inc. Scott has also held Chairman Positions at Novra Therapeutics, Inc. and Cidara Therapeutics, Inc.

Education Background

Scott Rocklage has a rich educational background. He studied at the University of California, Barkley where he graduated with a degree of Bachelor of Science in Chemistry. He later enrolled at the Massachusetts Institute of Technology where he earned his Ph.D. in Chemistry. Dr. Scott is a co-inventor and inventor of over 30 United States Patents.

Through his leadership, 5AM Ventures has grown to become a successful venture capital company. The company supports entities that develop solutions to solve healthcare-related needs. 5AM Ventures boasts of a strong team with vast experience in law, finance, science, medicine, and business operation.

With such a team behind him, Rocklage is confident that 5AM Ventures will keep doing great things. The company takes on various roles related to operating and managing businesses. It also serves as operations managers, strategists, and board members on short-term basis.

Read more: Scott Racklage | Bloomberg